MIRA Pharmaceuticals (NASDAQ:MIRA) Releases Earnings Results

MIRA Pharmaceuticals (NASDAQ:MIRA) released its quarterly earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, FiscalAI reports.

MIRA Pharmaceuticals Price Performance

Shares of MIRA stock traded up $0.04 during midday trading on Thursday, hitting $0.78. The company had a trading volume of 25,375 shares, compared to its average volume of 131,241. The stock has a market cap of $32.86 million, a price-to-earnings ratio of -0.60 and a beta of 1.54. The company’s 50 day simple moving average is $0.90 and its 200 day simple moving average is $1.04. MIRA Pharmaceuticals has a 52-week low of $0.60 and a 52-week high of $2.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings upgraded shares of MIRA Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, August 6th. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, MIRA Pharmaceuticals currently has a consensus rating of “Hold”.

Institutional Investors Weigh In On MIRA Pharmaceuticals

Several hedge funds have recently modified their holdings of the stock. Fifth Third Bancorp acquired a new position in MIRA Pharmaceuticals in the 4th quarter valued at $30,000. XTX Topco Ltd purchased a new stake in shares of MIRA Pharmaceuticals in the second quarter valued at about $26,000. Creative Planning purchased a new stake in shares of MIRA Pharmaceuticals in the second quarter valued at about $27,000. Two Sigma Investments LP boosted its holdings in shares of MIRA Pharmaceuticals by 129.8% in the third quarter. Two Sigma Investments LP now owns 45,703 shares of the company’s stock valued at $62,000 after acquiring an additional 25,816 shares in the last quarter. Finally, BlackRock Inc. acquired a new position in shares of MIRA Pharmaceuticals during the second quarter worth about $232,000. 35.16% of the stock is owned by institutional investors and hedge funds.

MIRA Pharmaceuticals Company Profile

MIRA Pharmaceuticals, Inc operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a patent pending oral ketamine analog under investigation to deliver ultra-rapid antidepressant effects for individuals battling treatment-resistant depression, major depressive disorder with suicidal ideation, and post-traumatic stress disorder.